Prot #CACZ885U2301: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-Based Doublet Chemotherapy with or without Canakinumab as First Line Therapy for Locally Advanced or Met